Compare GSBC & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSBC | PRCT |
|---|---|---|
| Founded | 1923 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.6M | 1.0B |
| IPO Year | 1996 | 2021 |
| Metric | GSBC | PRCT |
|---|---|---|
| Price | $79.49 | $21.35 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $65.00 | $35.44 |
| AVG Volume (30 Days) | 76.1K | ★ 966.6K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 17.68 | 1.71 |
| EPS | ★ 2.99 | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $31.34 |
| Revenue Next Year | $2.56 | $24.52 |
| P/E Ratio | $26.84 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $53.76 | $16.67 |
| 52 Week High | $82.91 | $40.10 |
| Indicator | GSBC | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 51.15 |
| Support Level | $76.29 | $21.28 |
| Resistance Level | $82.19 | $29.27 |
| Average True Range (ATR) | 1.49 | 1.05 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 73.46 | 38.32 |
Great Southern Bancorp Inc is a bank holding company. Through its subsidiaries, the company mainly offers a variety of banking and banking-related services, such as accepting deposits, granting loans and advances, offering mobile banking services, issuing debit and credit cards, safe deposit boxes, ATM facilities, and other related products and services. These services are offered through full-service retail banking offices and loan production offices located across different states in the U.S., including Missouri, Iowa, Kansas, Minnesota, Nebraska, Arkansas, and others.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.